Recent evidence has shown that the addition of PD-1/PD-L1 blockade therapy to platinum-based chemotherapy prolonged overall survival in advanced NSCLC patients, SCLC patients and head and neck cancer patients1,2,19–21. This evidence concerns the gene CD274 and non-small cell lung carcinoma.